The current role of acalabrutinib in the treatment of CLL

In this video, Catherine Coombs, MD, University of North Carolina, Chapel Hill, NC, discusses the importance of acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL), highlighting its role in the frontline setting and in the relapsed/refractory (R/R) setting. Dr Coombs also comments on the efficacy and tolerability of this agent based on findings from various clinical trials. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Be the first to comment